Pediatric Osteosarcoma: Identifying the elusive molecular signature and its relationship to this disease |
St. Jude Children's Research Hospital / Linda Hendershot, PhD |
Innovation Grants |
2019 |
Tennessee |
Novel Therapy of Heterogeneous B-cell Acute Lymphocytic Leukemia by Targeting Convergent Oncogenic Mediators STATs |
University of Alberta / Hasan Uludag, PhD |
Innovation Grants |
2019 |
Alberta |
Targeting microenvironment-induced TGFB signaling to overcome drug resistance in acute lymphoblastic leukemia |
St. Jude Children's Research Hospital / Charles Mullighan, MD |
Innovation Grants |
2019 |
Tennessee |
Norepinephrine Transporter-Targeted Pharmacotherapy of Aggressive Neuroblastoma |
Children's Hospital of Philadelphia / Michael Chorny, PhD |
Innovation Grants |
2019 |
Pennsylvania |
Therapeutic Targeting of the Disrupted Metabolic State in DIPG |
University of Michigan / Costas Lyssiotis, PhD & Sriram Venneti, MD/PhD |
Innovation Grants |
2019 |
Michigan |
The anti-tumor immune microenvironment in the Sonic Hedgehog subclass of medulloblastoma |
Emory University / Anna Kenney, PhD |
Innovation Grants |
2019 |
Georgia |
Targeting mechanisms of Siglec15-mediated immune evasion in hematologic malignancies |
Emory University / Christopher Porter, MD |
Innovation Grants |
2019 |
Georgia |
Using Splice Switching Oligonucleotides (SSOs) to target MDM2 for rhabdomyosarcoma therapy |
Research Institute at Nationwide Children's Hospital / Dawn Chandler, PhD |
Innovation Grants |
2019 |
Ohio |
Developing drugs to treat NT5C2 mediated resistance in pediatric ALL |
New York University School of Medicine / William Carroll, MD |
Innovation Grants |
2019 |
New York |
Identify Novel Druggable Targets to Treat Philadelphia chromosome-like B-Acute Lymphoblastic Leukemia |
Children's Hospital of Philadelphia / Wei Tong, PhD |
Innovation Grants |
2019 |
Pennsylvania |